share_log

首药控股(688197.SH)：核心自研产品均处于研发阶段，尚未有产品上市贡献销售收入

First Pharmaceutical Holdings (688197.SH): The core self-developed products are all in the R&D stage, and no products have yet been launched to contribute to sales revenue

Gelonghui Finance ·  Mar 14 06:26

On March 14, Gelonghui Holdings (688197.SH) announced an announcement of abnormal fluctuations in stock trading. The company's daily operations are all normal, and every effort is being made to promote clinical research on the core pipeline. As of the disclosure date of this announcement, the core self-developed product SY-707 is undergoing pre-NDA communication based on registered clinical phase III trial results; the NSCLC critical phase II trial of the third-generation ALK inhibitor SY-3505 against second-generation ALK inhibitor treatment failure is undergoing rapid enrollment, and a critical phase III clinical study on first-line treatment of ALK-positive NSCLC patients with crizotinib was officially launched in December 2023; the critical phase II trial of the selective RET inhibitor SY-5007 for RET positive NSCLC has been completed All subjects were enrolled, and the Phase III confirmatory clinical study was officially launched in July 2023, and is currently progressing rapidly. As of the disclosure date of this announcement, the company's core self-developed products are all in the R&D stage, and no products have been launched to contribute to sales revenue.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment